Angiotech anti-microbial catheters
This article was originally published in The Gray Sheet
Executive Summary
Vancouver firm initiates a 600-patient trial of drug-coated central venous catheter Jan. 5. The product, which will be submitted to FDA for 510(k)-clearance, is designed to prevent infections in critically ill patients with catheters inserted for extended periods. Angiotech describes the drug, 5-fluorouracil, as a "non-traditional anti-infective" because it is chemically different from currently used antibiotics, and, therefore, does not contribute to resistance to such drugs. Once enrollment is complete, the study, which will compare the product to an already approved anti-infective catheter, will take no more than 21 days, Anigotech says...